SM
Seol Matt
Chief Executive Officer at Hans Biomed
View Seol's Contact Info for Free. Sign Up and Get 50 Free Contacts Per Month.Get Started for Free
Work Experience
Chief Executive Officer
Apr 2024 - Present · 8 months
HansBiomed Latin America
Latin President
Jan 2019 - Apr 2024 · 5 years and 3 months
Company Details
11-50 Employees
At Hans Biomed USA, our mission is to embrace new challenges in the pursuit of improving the quality of life for all of humanity through revolutionary R&D in biotechnology. We specialize in aesthetic medical devices (MINT PDO threads, MINT microcannula), cosmetic products (klárdie skin boosters), bone graft material (SurFuse, ExFuse, ExOss, D-Sure, Sure Chip), and acellular dermal matrix (SureDerm, BellaCell HD), providing the best-in-quality products and service for providers worldwide. Hans Biomed USA is a pioneer of the aesthetic and biologics industry, having been recognized as the Top Aesthetic Company, Top Medical Thread Device, and Top Aesthetic Professional Team for 6 consecutive years by Aesthetic Everything. Our commitment to advancing medical treatments and technology related to regenerative medicine and tissue engineering is at the forefront of our mission. Hans Biomed USA www.hansbiomedusa.com https://www.instagram.com/hansbiomedusa https://vimeo.com/hansusa MINT PDO Threads and Microcannulas www.mintpdo.com https://www.instagram.com/mintpdo klárdie www.klardieusa.com https://www.instagram.com/klardieusa Hans Biomed Biologics Contact us for distribution opportunities biologics@hansbiomed.us
Year Founded
2011
Social Media
Linkedin
Industry
Biotechnology Research
HQ Location
140 Sylvan Ave Suite 301 Englewood Cliffs, New Jersey 07632, US
Keywords
BiologicsGuided Bone RegeneratioDBMADMMedical DeviceAestheticsSkin BoostersMicrocannulasThread LiftNonsurgical Rejuvenatio
Discover More About Cleveland Clinic

Find verified contacts of Seol Matt in seconds from 700M people profiles. Start now!

No Credit Card Needed. By signing up, you understand and agree to Futern's Terms and Policy.